PCRX Q1 2017 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q1 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$69M+5.8% YoY

Gross Profit

$45M64.5% margin

Operating Income

-$14M-20.3% margin

Net Income

-$20M-28.7% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

-5.0%

Cash Flow

Operating Cash Flow

$6,000

Free Cash Flow

-$4M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$600M

Total Liabilities

$329M

Stockholders' Equity

$271M

Cash & Equivalents

$109M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$65M	+5.8%
Gross Profit	$45M	$45M	-1.1%
Operating Income	-$14M	-$2M	-523.3%
Net Income	-$20M	-$4M	-415.5%